Studies showing putative involvement of Negr1 in psychiatric disorders

Literature Disease targeted Subject Main findings
Singh et al. 2019 [23] General psychiatric disorders negr1 −/− mouse

- Enlarged ventricle.

- Decreased number of parvalbumin-positive inhibitory interneurons in hippocampus.

- Hyperactivity in social interaction.

- Impaired social dominance behavior.

Maccarrone et al. 2013 [55] Major depressive disorder (MDD), Bipolar disorder, Schizophrenia (SCZ) Human

- Identification of association of Negr1 as a MDD-specific protein biosignature in cerebrospinal fluid of MDD patient.

Szczurkowska et al. 2018 [27] Autism spectrum disorder (ASD) negr1 −/− mouse

- Impaired ultrasonic vocalization.

- Increased latency to respond to thermal stimuli.

- Less sniffing, More grooming.

Ni et al. 2018 [70] Major depressive disorder (MDD), Alzheimer’s disease (AD) Human, mouse

- Identification of Negr1 as a common variants in the MDD GWAS loci with AD.

- Reduced mRNA expression in the entorhinal cortex and temporal cortex in human AD patient.

- Significant correlation of Negr1 mRNA expression level with both amyloid-β (Aβ) and tau (Tau) burden in AD mouse model.

Karis et al. 2018 [71] Schizophrenia (SCZ) Human

- Increased Negr1 transcript level in dorsolateral prefrontal cortex in SCZ patient.

Noh et al. 2019 [60] Major depressive disorder (MDD) negr1 −/− mouse

- Increased anxiety- and depressive-like behavior.

- Decreased hippocampal neurogenesis.

- Reduced Lipocalin-2 (Lcn2) expression in hippocampus.

- Impaired LTP and mEPSC in hippocampal dentate gyrus.

Amare et al. 2018 [56] Major depressive disorder (MDD) Human

- Identification of association of Negr1 in SSRI treatment response.

Exp Neurobiol 2020;29:1~10
© Exp Neurobiol